A New Targeted Model of Experimental Autoimmune Encephalomyelitis in the Common Marmoset

Brain Pathology

Volumn 26, Issue 4, 2016, Pages 452-464

  Stassart, Ruth Martha ^a   Helms, Gunther ^a   Garea Rodríguez, Enrique ^b,c   Nessler, Stefan ^a   Hayardeny, Liat ^d   Wegner, Christiane ^a   Schlumbohm, Christina ^c,e   Fuchs, Eberhard ^a,c,e   Brück, Wolfgang ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c GERMAN PRIMATE CENTER   (Germany)

^d TEVA PHARMACEUTICALS   (Israel)

^e Encepharm GmbH   (Germany)

Author keywords

common marmoset; demyelination; experimental autoimmune encephalomyelitis; immunomodulation; laquinimod; multiple sclerosis

Indexed keywords

2',3' CYCLIC NUCLEOTIDE 3' PHOSPHODIESTERASE; CALGRANULIN B; FREUND ADJUVANT; GADOBUTROL; GAMMA INTERFERON; GLIAL FIBRILLARY ACIDIC PROTEIN; IMMUNOGLOBULIN G ANTIBODY; LAQUINIMOD; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; PROTEIN NOGO A; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CALLITHRIX JACCHUS; CONTROLLED STUDY; DEMYELINATION; DISEASE MODEL; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; HISTOPATHOLOGY; HUMAN VERSUS NONHUMAN DATA; IMMUNOMODULATION; MALE; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIMATE MODEL;

EID: 84978520152     PISSN: 10156305     EISSN: 17503639     Source Type: Journal    
DOI: 10.1111/bpa.12292     Document Type: Article

References (22)

1. Boretius S, Schmelting B, Watanabe T, Merkler D, Tammer R, Czéh B et al (2006) Monitoring of EAE onset and progression in the common marmoset monkey by sequential high-resolution 3D MRI. NMR Biomed 19:41–49.
2. Brück W, Vollmer T (2013) Multiple sclerosis: oral laquinimod for MS—bringing the brain into focus. Nat Rev Neurol 9:664–665.
3. Brück W, Porada P, Poser S, Rieckmann P, Hanefeld F, Kretzschmar HA, Lassmann H (1995) Monocyte/macrophage differentiation in early multiple sclerosis lesions. Ann Neurol 38:788–796.
4. Brück W, Gold R, Lund BT, Oreja-Guevara C, Prat A, Spencer CM et al (2013) Therapeutic decisions in multiple sclerosis: moving beyond efficacy. JAMA Neurol 70:1315–1324.
5. Gardner C, Magliozzi R, Durrenberger PF, Howell OW, Rundle J, Reynolds R (2013) Cortical grey matter demyelination can be induced by elevated pro-inflammatory cytokines in the subarachnoid space of MOG-immunized rats. Brain 136:3596–3608.
6. Genain CP, Hauser SL (2001) Experimental allergic encephalomyelitis in the New World monkey Callithrix jacchus. Immunol Rev 183:159–172.
7. Haanstra KG, Jagessar SA, Bauchet A-L, Dousseau M, Fovet C-M, Heijmans N et al (2013) Induction of experimental autoimmune encephalomyelitis with recombinant human myelin oligodendrocyte glycoprotein in incomplete Freund's adjuvant in three non-human species. J Neuroimmune Pharmacol 5:1251–1264.
8. Helms G, Garea-Rodriguez E, Schlumbohm C, König J, Dechent P, Fuchs E et al (2013) Structural and quantitative neuroimaging of the common marmoset monkey using a clinical MRI system. J Neurosci Methods 215:121–131.
9. Jagessar SA, Kap YS, Heijmans N, van Driel N, van Straalen L, Bajramovic JJ et al (2010) Induction of progressive demyelinating autoimmune encephalomyelitis in common marmoset monkeys using MOG34-56 peptide in incomplete Freund adjuvant. J Neuropathol Exp Neurol 69:372–385.
10. Jagessar SA, Vierboom M, Blezer EL, Bauer J, Hart BA, Kap YS (2013) Overview of models, methods, and reagents developed for translational autoimmunity research in the common marmoset (Callithrix jacchus). Exp Anim 62:159–171.
11. Kap YS, Laman JD, ‘t Hart BA (2010) Experimental autoimmune encephalomyelitis in the common marmoset, a bridge between rodent EAE and multiple sclerosis for immunotherapy development. J Neuroimmune Pharmacol 5:220–230.
12. Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711–715.
13. Kuhlmann T, Miron V, Cui Q, Wegner C, Antel J, Brück W (2008) Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis. Brain 131:1749–1758.
14. Lassmann H, Brück W, Lucchinetti C (2001) Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 3:115–121.
15. Merkler D, Böschke R, Schmelting B, Czéh B, Fuchs E, Brück W et al (2006) Differential macrophage/microglia activation in neocortical EAE lesions in the marmoset monkey. Brain Pathol 16:117–123.
16. Merkler D, Ernsting T, Kerschensteiner M, Brück W, Stadelmann C (2006) A new focal EAE model of cortical demyelination: multiple sclerosis-like lesions with rapid resolution of inflammation and extensive remyelination. Brain 129:1972–1983.
17. Merkler D, Schmelting B, Czéh B, Fuchs E, Stadelmann C, Brück W (2006) Myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis in the common marmoset reflects the immunopathology of pattern II multiple sclerosis lesions. Mult Scler 12:369–374.
18. Nessler S, Boretius S, Stadelmann C, Bitter A, Merkler D, Hartung HP et al (2007) Early MRI changes in a mouse model of multiple sclerosis are predictive of severe inflammatory tissue damage. Brain 130:2186–2198.
19. Pomeroy IM, Matthews PM, Frank JA, Jordan EK, Esiri MM (2005) Demyelinated neocortical lesions in marmoset autoimmune encephalomyelitis mimic those in multiple sclerosis. Brain 128:2713–2721.
20. Popescu BF, Lucchinetti CF (2012) Pathology of demyelinating diseases. Annu Rev Pathol 7:185–217.
21. ‘t Hart BA, Massacesi L (2009) Clinical, pathological, and immunologic aspects of the multiple sclerosis model in common marmosets (Callithrix jacchus). J Neuropathol Exp Neurol 68:341–355.
22. ‘t Hart BA, Laman JD, Bauer J, Blezer E, van Kooyk Y, Hintzen RQ (2004) Modelling of multiple sclerosis: lessons learned in a non-human primate. Lancet Neurol 3:588–597.